Free Trial

Medpace (MEDP) Stock Price, News & Analysis

Medpace logo
$542.38 -2.03 (-0.37%)
As of 02:12 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Medpace Stock (NASDAQ:MEDP)

Advanced

Key Stats

Today's Range
$537.86
$554.14
50-Day Range
$453.34
$544.41
52-Week Range
$250.05
$554.14
Volume
300,436 shs
Average Volume
424,117 shs
Market Capitalization
$15.24 billion
P/E Ratio
40.33
Dividend Yield
N/A
Price Target
$430.60
Consensus Rating
Reduce

Company Overview

Medpace Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
87th Percentile Overall Score

MEDP MarketRank™: 

Medpace scored higher than 87% of companies evaluated by MarketBeat, and ranked 134th out of 935 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Medpace has received a consensus rating of Reduce. The company's average rating score is 1.94, and is based on 2 buy ratings, 12 hold ratings, and 3 sell ratings.

  • Downside Risk

    Medpace has a consensus price target of $430.60, representing about 20.6% downside from its current price of $542.38.

  • Amount of Analyst Coverage

    Medpace has been the subject of 14 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Medpace's stock forecast and price target.
  • Earnings Growth

    Earnings for Medpace are expected to grow by 11.15% in the coming year, from $12.29 to $13.66 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Medpace is 40.33, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 43.25.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Medpace is 40.33, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 29.24.

  • Price to Earnings Growth Ratio

    Medpace has a PEG Ratio of 3.31. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Medpace has a P/B Ratio of 20.42. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Medpace's valuation and earnings.
  • Percentage of Shares Shorted

    9.15% of the float of Medpace has been sold short.
  • Short Interest Ratio / Days to Cover

    Medpace has a short interest ratio ("days to cover") of 4.6.
  • Change versus previous month

    Short interest in Medpace has recently decreased by 5.45%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Medpace does not currently pay a dividend.

  • Dividend Growth

    Medpace does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    9.15% of the float of Medpace has been sold short.
  • Short Interest Ratio / Days to Cover

    Medpace has a short interest ratio ("days to cover") of 4.6.
  • Change versus previous month

    Short interest in Medpace has recently decreased by 5.45%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Medpace has a news sentiment score of 1.06. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.50 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 21 news articles for Medpace this week, compared to 16 articles on an average week.
  • Search Interest

    11 people have searched for MEDP on MarketBeat in the last 30 days. This is an increase of 175% compared to the previous 30 days.
  • MarketBeat Follows

    6 people have added Medpace to their MarketBeat watchlist in the last 30 days. This is an increase of 500% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Medpace insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $74,111,427.00 in company stock.

  • Percentage Held by Insiders

    20.30% of the stock of Medpace is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    77.98% of the stock of Medpace is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Medpace's insider trading history.
Receive MEDP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Medpace and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

MEDP Stock News Headlines

Preview: Medpace Hldgs's Earnings
Shots officially fired…
Elon Musk just declared war on the wireless giants with a $17 billion spectrum deal that gives SpaceX the rights to deliver direct-to-cell service nationwide — a move tech analyst Jeff Brown says could shape the backbone of the coming space economy and create fortunes on a scale not seen since the rise of NVIDIA.tc pixel
See More Headlines

MEDP Stock Analysis - Frequently Asked Questions

Medpace's stock was trading at $332.23 at the beginning of 2025. Since then, MEDP shares have increased by 63.3% and is now trading at $542.38.

Medpace Holdings, Inc. (NASDAQ:MEDP) released its quarterly earnings results on Monday, July, 21st. The company reported $3.10 earnings per share for the quarter, beating analysts' consensus estimates of $3.00 by $0.10. Medpace's revenue for the quarter was up 14.2% on a year-over-year basis.
Read the conference call transcript
.

Medpace (MEDP) raised $150 million in an initial public offering (IPO) on Thursday, August 11th 2016. The company issued 7,000,000 shares at a price of $20.00-$23.00 per share. Jefferies, Credit Suisse, UBS Investment Bank and Wells Fargo Securities acted as the underwriters for the IPO and Baird and William Blair were co-managers.

Top institutional shareholders of Medpace include Riverbridge Partners LLC (1.30%), Boston Trust Walden Corp (0.54%), Pacer Advisors Inc. (0.40%) and Annex Advisory Services LLC (0.36%). Insiders that own company stock include Medpace Investors, Llc, August J Troendle, Susan E Burwig, Jesse J Geiger, Stephen P Ewald, Cornelius P Mccarthy III, Kevin M Brady, Fred B Davenport Jr, Ashley M Keating and Robert O Kraft.
View institutional ownership trends
.

Shares of MEDP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Medpace investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), McKesson (MCK), Arista Networks (ANET), Adobe (ADBE) and ServiceNow (NOW).

Company Calendar

Last Earnings
7/21/2025
Today
10/21/2025
Next Earnings (Estimated)
10/22/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Medical Services
Sub-Industry
Business Services
Current Symbol
NASDAQ:MEDP
CIK
1668397
Employees
5,900
Year Founded
1992

Price Target and Rating

High Price Target
$575.00
Low Price Target
$305.00
Potential Upside/Downside
-20.9%
Consensus Rating
Reduce
Rating Score (0-4)
1.94
Research Coverage
17 Analysts

Profitability

EPS (Trailing Twelve Months)
$13.45
Trailing P/E Ratio
40.48
Forward P/E Ratio
44.30
P/E Growth
3.31
Net Income
$404.39 million
Net Margins
18.74%
Pretax Margin
22.20%
Return on Equity
67.66%
Return on Assets
21.86%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.43
Quick Ratio
0.43

Sales & Book Value

Annual Sales
$2.11 billion
Price / Sales
7.25
Cash Flow
$14.38 per share
Price / Cash Flow
37.85
Book Value
$26.56 per share
Price / Book
20.50

Miscellaneous

Outstanding Shares
28,090,000
Free Float
22,390,000
Market Cap
$15.29 billion
Optionable
Optionable
Beta
1.40

Social Links

Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:MEDP) was last updated on 10/21/2025 by MarketBeat.com Staff
From Our Partners